News
BRVE
27.02
+1.43%
0.38
Weekly Report: what happened at BRVE last week (0907-0911)?
Weekly Report · 1d ago
Goldman Sachs Remains a Buy on Braveheart Bio, Inc. (BRVE)
TipRanks · 6d ago
Analysts Offer Insights on NA Companies: IMAX (IMAX) and Braveheart Bio, Inc. (BRVE)
TipRanks · 6d ago
Braveheart Posts Wider Loss In Q2 As BHB-1893 Advances In HCM Development
NASDAQ · 6d ago
Braveheart Bio Q2 EPS $(2.51)
Benzinga · 6d ago
Braveheart Bio, Inc. reports Q2 results
Seeking Alpha · 6d ago
*Braveheart Bio 2Q Loss/Shr $2.51 >BRVE
Dow Jones · 6d ago
Press Release: Braveheart Bio Reports Second -2-
Dow Jones · 6d ago
Press Release: Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 6d ago
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
TipRanks · 09/08 10:01
Weekly Report: what happened at BRVE last week (0831-0904)?
Weekly Report · 09/07 10:32
Analysts Offer Insights on NA Companies: Braveheart Bio, Inc. (BRVE) and TeraWulf Inc (WULF)
TipRanks · 09/07 08:10
Primary Markets Group August IPO Update
Seeking Alpha · 09/05 06:30
Braveheart Bio to Participate in Cantor Global Healthcare Conference
Barchart · 09/01 15:30
This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 09/01 12:05
Braveheart Bio Price Target Announced at $48.00/Share by Goldman Sachs
Dow Jones · 08/31 18:12
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Benzinga · 08/31 18:01
Midday Fly By: Aon buying USI, Lilly to acquire Merida
TipRanks · 08/31 16:01
Braveheart Bio Initiated at Buy by TD Cowen
Dow Jones · 08/31 14:42
Braveheart Bio Price Target Announced at $48.00/Share by Jefferies
Dow Jones · 08/31 14:31
More
Webull provides a variety of real-time BRVE stock news. You can receive the latest news about Braveheart Bio through multiple platforms. This information may help you make smarter investment decisions.
About BRVE
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.